menu
    • menu
    [{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Institutional Review Board","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Sublingual Chewing Gum","sponsorNew":"Tauriga Sciences \/ Institutional Review Board","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Institutional Review Board"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Sublingual Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Kratom Extract","moa":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tauriga Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Tauriga Sciences

    Menu

    Tauriga Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tauriga Sciences Inc. Formally Submits its Clinical Study Protocol to the Institutional Review Board

                            Details : The purpose of this clinical study is to examine the effects of different cannabidiol doses on reducing the frequency and severity of nausea in otherwise healthy pregnant women with excessive first trimester emesis and the diagnosis of hyperemesis gravid...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 17, 2021

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tauriga Sciences, Inc. Receives Notice of Publication from the U.S. Patent and Trademark Office

                            Details : Cannabidiol, is the second most prevalent active ingredient in cannabis (marijuana) used for anxiety, pain, a muscle disorder called dystonia, Parkinson disease, Crohn disease, and many other conditions.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 01, 2021

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Kratom Extract

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tauriga Sciences Inc. Commences Development of Kratom Extract Infused Chewing Gum

                            Details : Tauriga commenced the development of a proprietary Kratom extract infused supplement chewing gum for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 07, 2021

                            Lead Product(s) : Kratom Extract

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tauriga Sciences Inc. Receives Notification From the PCT That Its International Patent Application Has Been Pu...

                            Details : Company’s proposed pharmaceutical, Cannabinoid based, chewing Gum product (sublingual absorption-delivery system) under development for the treatment of nausea derived from active chemotherapy treatment.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 06, 2021

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Sponsor : Institutional Review Board

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Tauriga Sciences Inc. Completes Funding of the Study Protocol Phase of its Recently Initiated Clinical Trial

                            Details : The Company’s proposed Cannabidiol delivery system (via: sublingual absorption / oral mucosa), utilizes its proprietary Cannabidiol infused chewing gum platform.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 13, 2021

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Sponsor : Institutional Review Board

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Tauriga Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tauriga Sciences Initiates Trial to Examine the Effects of Cannabidiol Doses on Pregnant Women with Diagnosis ...

                            Details : The clinical trial has been planned as a prospective, double-blind, placebo-controlled study, to examine the: Effects of different Cannabidiol doses on reducing the frequency and severity of nausea in otherwise healthy pregnant women with excessive first...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 31, 2021

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth